Rare immune-related adverse effect of pembrolizumab: pulmonary hypertension
Articles > Article · 2024
Authors: Caner ACAR, Gökhan Sahin, Haydar Çagatay Yüksel, Burçak Karaca
Journal of Chemotherapy, International, WoS, 2024, vol 37, pp 193-198
DOI: 10.1080/1120009x.2024.2349858
Summary
PD-1 blockade. Recent studies have shown its effectiveness in treating various solid organ tumours. However, unlike cytotoxic chemotherapeutic agents, pembrolizumab may cause immune-related adverse effects. These immune-related adverse effects are generally mild, although patients who experience grade-three or higher side effects may require hospitalisation. In particular, cardiopulmonary side effects are associated with high mortality rates. We report the case of a 24-year-old female patient with alveolar soft part sarcoma accompanied by rare and difficult-to-treat pulmonary hypertension induced by pembrolizumab.